Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Efficacy of Wilms' Tumor Gene (WT1) MRNA-electroporated Autologous Dendritic Cell Vaccination in Patients with Solid Tumors: a Phase I/feasibility Study

NCT01291420 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT01291420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01291420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Efficacy of Wilms' Tumor Gene (WT1) MRNA-electroporated Autologous Dendritic Cell Vaccination in Patients with Solid Tumors: a Phase I/feasibility Study
Lead sponsor
University Hospital, Antwerp
Phase
Phase 1/2
Overall status
Completed
Start date
May 3, 2010
Completion date
November 2, 2017
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancers, colorectal tumors, glioblastoma, malignant mesothelioma, renal cell carcinoma, sarcomas